Hepatocellular Carcinoma Surveillance—Experience from Croatian Referral Centre for Chronic Liver Diseases
- 27 Downloads
For patients at high-risk of developing hepatocellular carcinoma (HCC), biannual ultrasound surveillance has long been recommended, in order to detect the tumor in the early, potentially curative stages. However, globally reported HCC surveillance rates vary greatly, ranging from as low as 1.7 to as high as 80%. Our aim was to assess the utilization of surveillance with biannual ultrasound in high-risk Croatian patients and to identify the factors that impact the implementation of the recommended protocol.
This retrospective study included 145 newly diagnosed HCC patients in the period from January 2010 to September 2015. We identified low-risk and high-risk patients. The latter were further subdivided into the regular biannual ultrasound surveillance group and the non-surveillance group. The groups were compared according to demographic characteristics and BCLC stage at the time of HCC diagnosis.
Among 145 patients, 80 patients were classified as high-risk according to EASL criteria. During the relevant period, 28.7% underwent regular surveillance, while 71.25% did not. Younger patients were more likely to undergo surveillance (OR 0.935 CI 0.874–0.999; p = 0.05). The patients who underwent regular surveillance had a higher chance of being diagnosed at a curative stage (BCLC 0 or A) (OR 3.701 CI 1.279–10.710; p < 0.05).Gender was not a predictor of participation in the regular surveillance protocol. Among the high-risk patients who did not undergo regular surveillance, 56.1% were not aware of the chronic liver disease prior to the HCC diagnosis.
HCC surveillance is still underutilized in high-risk Croatian patients despite its obvious benefits possibly due to the untimely diagnosis of the chronic liver disease.
KeywordsHepatocellular carcinoma Surveillance Ultrasonography
This study was conducted as an original study at the Department of Gastroenterology, University Hospital Centre Zagreb, which is a referral center for treatment of chronic liver diseases.
Compliance with Ethical Standards
This study was approved by the ethics committee of the University Hospital Centre Zagreb (approval number—02/21 AG) and was conducted in compliance with the Helsinki Declaration.
- 3.International Agency for Research on Cancer (2016, September 22). Cancer Mortality Database. Retrieved from http://www-dep.iarc.fr/. Accessed 30 Sept 2016.
- 10.Bralic LV. Hepatocelularni karcinom – novosti u dijagnostici, praćenju i liječenju te uloga liječnika obiteljske medicine. Acta Med Croatica. 2015;69:327–32.Google Scholar
- 11.Croatian National Institute of Public Health (2014, May 2). Croatian Health Service Yearbook 2013. Retrieved from https://www.hzjz.hr/wp-content/uploads/2014/12/Ljetopis_2013__.pdf. Accessed 26 Aug 2016.
- 14.Hirata A, Hirata T, Takahashi Y, Nakayama T. Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database. Hepatol Res. 2017;47(4):283-292.Google Scholar
- 18.Ly CL, Wong LL. Ethnicity as a predictive factor for hepatocellular carcinoma screening among patients in Hawaii. Ethn Dis. 2014;24(3):376–81.Google Scholar
- 21.Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis. 2011;43(11):875–80.Google Scholar
- 25.Henrion J, Libon E, De Maeght S, Schapira M, Ghilain JM, Maisin JM, et al. Surveillance for hepatocellular carcinoma: compliance and results according to the aetiology of cirrhosis in a cohort of 141 patients. Acta Gastroenterol Belg. 2000;63(1):5–9.Google Scholar
- 30.Ganslmayer M, Hagel A, Dauth W, Zopf S, Strobel D, Müller V, et al. A large cohort of patients with hepatocellular carcinoma in single European centre: aetiology and prognosis now and in a historical cohort. Swiss Med Wkly. 2014;144:w13900.Google Scholar
- 32.Opriță R, Diaconescu IB, Lupu G, Lupu A, Cristea B, Bratu MR. Hepatocellular carcinoma among cirrhotics- utility of screening and surveillance programs—review article. J Med Life. 2014;7(4):477–80.Google Scholar
- 33.World Health Organisation (2014). Global status report on alcohol and health 2014. Retrieved from http://apps.who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf. Accessed 26 Aug 2016.
- 34.World Health Organisation (2014). Country profiles 2014, Croatia. Retrieved from http://www.who.int/substance_abuse/publications/global_alcohol_report/profiles/hrv.pdf?ua=1. Accessed 26 Aug 2016.
- 35.European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC; 2010 https://doi.org/10.2900/30933
- 36.Kaić B, Vilibić-Cavlek T, Filipović SK, Nemeth-Blazić T, Pem-Novosel I, Vucina VV, Simunović A, Zajec M, Radić I, Pavlić J, Glamocanin M,. [Epidemiology of viral hepatitis]. [Article in Croatian] Acta Med Croatica. 2013;67(4):273-9.Google Scholar
- 37.Hadjittofi C, Athanasopoulos PG, Koti RS, Konstantinidou SK, Davidson BR. Long-term survival with repeated resections of recurrent hepatocellular carcinoma in a non-cirrhotic liver: case report and brief review of the literature. Ann Transl Med. 2016;4(6):112.Google Scholar
- 38.Schütte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, Bretschneider 38. T, Arend J, Ricke J, Malfertheiner P. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the noncirrhotic liver. BMC Gastroenterol. 2014;14:117. https://doi.org/10.1186/1471-230X-14-117